Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Organon & Co.

35 indications, side-by-side phase, drug & LoA

$13.44

-0.01 (-0.07%)

A 84Pipeline Score Undervalued Pharma · Commercial
Market Cap
3.53 B
EPS
0.95
P/E Ratio
14.31 $
Value Trade
34.38 M
SEC Financials
Q1 2026

  • Dilution Risk

    5%

  • Revenue

    1.46 B

  • R&D Expenses

    93.00 M

  • Operating CF

    225.00 M

  • Total Assets

    13.00 B

  • Total Liabilities

    12.09 B

  • Equity

    903.00 M

  • D/E Ratio

    12,345

0.45 %
Week
49.72 %
1 Month
74.64 %
3 Month
87.57 %
6 Month
-65.12 %
5 Year
-56.68 %
All Time
Cash Data
Profitable

  • Cash Position

    1.12 B

  • Monthly Burn

    -

  • Runway

    12,345 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 4, 2026
Overview
Volume
1.82 M
52 Week Range
5.69 - 13.48
% held by Insiders
0.48 %
% held by Institutions
76.31 %
Enterprise Value
10.98 B
Total Shares
262.52 M
Short %
6.91 %
Float Shares
261.47 M
Company Description
HQ: 30 HUDSON STREET, JERSEY CITY,...
Employees:10,000
https://www.organon.com

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
A84
Pipeline Score
$52.9B
Pipeline Value
Undervalued
Valuation Signal
64
Drugs Scored
15.0x
rNPV / MCap
Top 98%
Small Cap
(rank 19 of 905)
Percentile Rank
Organon & Co. earns an A-grade pipeline score (84/100), with $95.8B risk-adjusted pipeline value, led by MK0653A, ezetimibe simvastatin in Type 2 Diabetes Mellitus (Phase 3).
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
MK0653A, ezetimibe simvastatin
Small molecule		HypercholesterolemiaPhase 3NCT0009269053% $13.6B COMPLETED 7,000 - -Mar 1, 2004 -May 10, 2024
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
VTAMA (tapinarof)
topical treatment of plaque psoriasis in adults,topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
Phase 3
2025-07-07
VTAMA (tapinarof)
topical treatment of plaque psoriasis in adults,topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
Phase 3
2025-07-07
VTAMA (tapinarof)
topical treatment of plaque psoriasis in adults,topical treatment of atopic dermatitis in adults and pediatric patients 2 years of age and older
Phase 3
2025-07-07
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in OGN
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
OGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
OGN
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
OGN Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
OGN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
2026-07-170 0.00 0 0 - - - - - -
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Organon & Co. (OGN) News & Alerts
-
Saturday, June 13, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How OGN ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Atopic Dermatitis #8 of 25 PHASE 3 Tapinarof , 1% + Vehicle
LLY ABBV PFE
$20.76B 0.98 CONTENDER
Psoriasis #10 of 15 PHASE 3 tapinarof , 1%
JNJ BMY ABBV
$26.66B 0.98 CONTENDER
Esophageal Cancer #17 of 39 PHASE 2 Pembrolizumab + Trastuzumab + FLOT
MRK AZN ONC
$1.85B 0.55 FOLLOWER